Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2014 Jan 20;9(1):e85001. doi: 10.1371/journal.pone.0085001

Pneumococcal Carriage in Sub-Saharan Africa—A Systematic Review

Effua Usuf 1,*, Christian Bottomley 2, Richard A Adegbola 3, Andrew Hall 4
Editor: Caroline L Trotter5
PMCID: PMC3896352  PMID: 24465464

Abstract

Background

Pneumococcal epidemiology varies geographically and few data are available from the African continent. We assess pneumococcal carriage from studies conducted in sub-Saharan Africa (sSA) before and after the pneumococcal conjugate vaccine (PCV) era.

Methods

A search for pneumococcal carriage studies published before 2012 was conducted to describe carriage in sSA. The review also describes pneumococcal serotypes and assesses the impact of vaccination on carriage in this region.

Results

Fifty-seven studies were included in this review with the majority (40.3%) from South Africa. There was considerable variability in the prevalence of carriage between studies (I-squared statistic = 99%). Carriage was higher in children and decreased with increasing age, 63.2% (95% CI: 55.6–70.8) in children less than 5 years, 42.6% (95% CI: 29.9–55.4) in children 5–15 years and 28.0% (95% CI: 19.0–37.0) in adults older than 15 years. There was no difference in the prevalence of carriage between males and females in 9/11 studies. Serotypes 19F, 6B, 6A, 14 and 23F were the five most common isolates. A meta-analysis of four randomized trials of PCV vaccination in children aged 9–24 months showed that carriage of vaccine type (VT) serotypes decreased with PCV vaccination; however, overall carriage remained the same because of a concomitant increase in non-vaccine type (NVT) serotypes.

Conclusion

Pneumococcal carriage is generally high in the African continent, particularly in young children. The five most common serotypes in sSA are among the top seven serotypes that cause invasive pneumococcal disease in children globally. These serotypes are covered by the two PCVs recommended for routine childhood immunization by the WHO. The distribution of serotypes found in the nasopharynx is altered by PCV vaccination.

Introduction

The human nasopharynx is the main reservoir for pneumococci. The bacteria which adhere to pharyngeal epithelial cells through epithelial receptor molecules may be acquired very early in life [1], [2], and in most children the pneumococcus is present in the nasopharynx at some point in the first few years of life [3]. Carriage is generally higher in developing countries and among economically deprived populations [4], [5]. The prevalence of carriage might also vary between developing countries. In one study, Abdullahi et al suggested that colonisation prevalence in East and Southern Africa is substantially lower than in the Gambia [6]. High prevalence have however been reported in Ethiopia and Mozambique.

Carriage is a prerequisite for disease [3], [7] and because it is much more common than a disease outcome, it may be a valuable measure of the efficacy of new pneumococcal vaccines [8]. The relation between carriage and disease was first demonstrated in a cohort of infants [9]. Subsequent studies showed that carriage is a risk factor for acute and recurrent otitis media in children [10], [11]. Other studies have shown that bacterial carriage densities may be related to the risk of disease in adults and children [12], [13], and O'Brien et al have suggested that PCV may reduce carriage density in children [14].

Since the introduction of PCV, several studies have reported a reduction in invasive pneumococcal disease (IPD). However, this is frequently accompanied by a change in the distribution of circulating serotypes. A decrease in vaccine type (VT) IPD and an increase in non-vaccine type (NVT) IPD have been reported in America [15], Spain [16], Canada [17] and Australia [18]. In particular, serotype 19A has been isolated more frequently after the introduction of PCV 7 [19][22].

This review of pneumococcal carriage in sSA aims to: 1) describe the variability in carriage prevalence across countries in sSA; 2) describe the distribution of serotypes, and 3) assess the impact of pneumococcal vaccination on carriage of VT and NVT serotypes.

Methods

A comprehensive literature search strategy was developed to identify published articles describing pneumococcal carriage in sSA (Appendix S1). The search was conducted in December 2011 using the electronic databases MEDLINE (from 1950), EMBASE (from 1947) and African Index Medicus (AIM). To ensure the retrieval of relevant articles, the search was performed by exploring and combining medical subject headings (MeSH) and free search terms relating to carriage, nasopharyngeal, oropharyngeal, Streptococcus pneumoniae, serotypes, pneumococcal vaccine and specific names of the African countries. Titles and abstracts were reviewed and duplicates, non-relevant studies, and those involving streptococcal infections other than S. pneumoniae were excluded (Figure 1). The full texts of potential papers were then screened for eligibility.

Figure 1. Flow chart for eligible articles.

Figure 1

Inclusion and exclusion criteria

The review was limited to studies from countries within the sSA region that reported the prevalence of carriage with or without serotyping of the pneumococcal isolates. We used data from both hospital and community based studies that collected swabs from either the nasopharynx or oropharynx. The search was limited to human subjects but there was no restriction on the age of participants, study design or language of publication. Bibliographies of relevant papers and review papers were searched to identify articles that may have been missed in the electronic search.

Data analysis

Data were obtained for the following variables: prevalence of S. pneumoniae, country, first author, year the study was conducted (or year of publication if the study year was not reported), age of participants, number of swabs collected per individual, health of the population swabbed, rural or urban setting, and season or months of the year when the study was conducted. The data were entered in an Excel spread sheet and Stata version 12 was used for all analyses. For studies with multiple swabs per individual, only results from the first swab were included in the analysis and for those with interventions, either PCV or other interventions such as antibiotics, only the control arm was included in the analysis. To assess the impact of PCV we used data from randomised trials where PCV was the intervention. The extracted data were reviewed independently by a second reviewer who checked the data to ensure completeness using the template prepared for data extraction.

To describe the prevalence of carriage by age, the studies were grouped as: <5 years (children), 5–15 years (children), and >15 years (adults). Studies that recruited children in both age groups were assigned to the age group 5–15 years. Studies where participants were recruited across child and adult age groups, and where suitable stratified results were unavailable were excluded from the analysis of carriage by age. A random-effects model was used to summarise carriage by age group across the different studies. Studies where the standard error of the prevalence could not be computed were excluded from this analysis. The effects of region, season and urban/rural location on carriage were examined by comparing between studies using random effects model (meta-regression). For each study that reported carriage by gender, the absolute difference in prevalence between males and females (risk difference) was calculated and statistical significance was determined using Fisher's exact test.

Data from four of the studies were pooled to assess the impact of PCV on overall carriage and the carriage of VT and NVT serotypes among children 9 to 24 months. In all four studies children who received no PCV were compared with children who received at least three doses of PCV. Random effects models were used to estimate the average effect of PCV (DerSimonian-Laird estimate) across studies and to assess the degree of heterogeneity between studies.

Serotypes isolated in each study were ranked in order of prevalence and the five most prevalent serotypes in each study were identified. For each serotype, we determined the proportion of studies in which it was among five most prevalent serotypes.

Quality of the studies

The studies were reviewed for quality using the WHO guidelines for conducting nasopharyngeal studies. The guidelines are for the material used for sample collection, the technique of sample collection, and the transport media [23]. For each study, we identified potential sources of bias in the method of selection of study subjects.

Results

Characteristics of the studies

A total of 57 studies were included in this review (Table 1). Southern Africa contributed the most studies, 23(40.3%). Twenty studies (35.1%) were from West Africa with more than half of these from The Gambia. There were 12(21.1%) and 2(3.5%) studies from East and Central Africa respectively.

Table 1. Characteristics of studies included in the review (n = 32,253).

First author,(ref) Country Year Age Population Swab type Route Swabs/person
Central Africa
Rowe, [47] CAR 1995 2 m–58 m opda c.alginate NPS single
Ndip, [48] Cameron 2004 10 y–21 y schoolb ns OPS single
East Africa
Ringertz, [49] Ethiopia 1987 <5 y comm c.alginate NPS single
Rusen, [50] Kenya 1990 <5 y opdc c.alginate NPS single
Joloba, [51] Uganda 1995 <3 y opdd c.alginate NPS single
Batt, [52] Tanzania 2000 <7 y comm cotton OPS single
Scott, [53] Kenya 2000 <7 y comm/hosp dacron NPS single
Nyandiko, [54] Kenya 2003 <42 m opde dacron NPS single
Abdullahi, [6] Kenya 2004 all comm rayon NPS twice
Blossom, [55] Uganda 2004 20 y–55 y HIV BBL OPS single
Abdullahi, [56] Kenya 2006 <5 y opdf rayon NPS single/multipleg
Haug, [57] Ethiopia 2003/6 1 y–5 y comm ns NPS single
Skalet, [58] Ethiopia 2006 <10 y comm ns NPS single
Scott, [27] Kenya 2004/7 <1 y EPI rayon NPS single
Southern Africa
Jacobs, [59] South Africa 1977 all hosph c.alginate NPS single
Klugman, [60] South Africa 1977 <5 yi DCC c.alginate NPS single
Robins-Browne, [61] South Africa 1981 <12 y hosp c.alginate NPS single
Oppenheim, [62] South Africa 1983 <10 y hosp c.alginate NPS multiple
Frederiksen, [63] Zambia 1986 <10 y opdd cotton OPS single
Woolfson, [64] Zambia 1994 <6 y opda c.alginate NPS single
Mthwalo, [65] Lesotho 1995 <5 y comm c.alginate NPS single
Yomo, [66] Malawi 1995 <5 y MCH cotton both multiple
Feikin, [67] Malawi 1997 2 w–59 m opdf ns NPS single
Feikin, [68] Malawi 1997 2 w–59 m opda ns NPS multiple
Huebner, [69] Botswana 1997 2 m–5 y opd/ward c.alginate NPS single
Gordon, [70] Malawi 1998 all ns cotton NPS single
McNally, [36] South Africa 2001 1 m–59 m hospj wire NPS single
Cotton, [71] South Africa 2002 8 w–5 y HIV wire NPS single
Pemba, [45] South Africa 2002 adults HIV c.alginate Both twice
Gill, [45] Zambia 2003 6 w–18 m HIV+ve/−ve c.alginate NPS single/multipleg
Valles, [72] Mozambique 2003 <5 y opd c.alginate NPS Single
von Gottberg, [73] South Africa 2006 all hospk dacron NPS single
Mbelle, [28] South Africa 1999l <1 y comm c.alginate NPS multiple
Huebner, [74] South Africa 2000l 2 m–5 y clinicd c.alginate NPS single
Mwenya, [75] Zambia 2002 6 m–14 y HIV rayon NPS single
Marcus, [76] South Africa 1993 3 m–8 y school c.alginate NPS single
West Africa
Hansman, [77] Nigeria 1977 ns opda ns NPS single
Lloyd- Evans, [78] Gambia 1989 all comm/hosp cotton NPS single/multipleg
Obaro, [30] Gambia 1995 2 y comm ns NPS single
Denno, [79] Ghana 1996 <1 y opde wire NPS single
Kacou-Ndouba, [80] Ivory Coast 1997 <5 y EPI c.alginate NPS single
Obaro, [25] Gambia 2000 <1 y EPI cotton NPS twice
Darboe, [81] Gambia 2001 all comm c.alginate NPS multiple
Adegbola, [82] Gambia 2001l 3–4 y comm c.alginate NPS single
Hill, [83] Gambia 2003/4 all comm c.alginate NPS single
Hill, [2] Gambia 2008l <1 y comm c.alginate NPS multiple
Nwachukwu, [37] Nigeria 2008l 2 m–59 m EPI ns NPS single
Bere, [84] Burkina Faso 2000 <5 y MCH c.alginate NPS single
Cheung, [29] Gambia 2003 9 m–27 m comm ns NPS multiple
Kandakai-Olukemi, [85] Nigeria 2009l 15 y–25 y school cotton NPS single
Mureithi, [86] Gambia 2009l 19 y–50 y comm ns NPS single
Darboe, [1] Gambia 2010l <1 y clinic c.alginate NPS multiple
Donkor, [87] Ghana 2006 <13 y hospm ns NPS single
Hill, [88] Gambia 2010l All comm ns NPS multiple
Kacou-N'douba, [89] Ivory Coast 2010l <5 y ns ns ns single
Ota, [26] Gambia 2011l <1 y EPI c.alginate NPS single
Roca, [24] Gambia 2006/8 All ages comm c.alginate NPS single

Ref- reference, N-number of individuals, ns- not stated; NPS- Nasopharyngeal swab; OPS- Oropharyngeal swab; c.alginate- Calcium Alginate; w-week, m-months, y-years, comm- community, opd-outpatient department, hosp-hospital, EPI -Expanded programme on immunisation clinic, DCC- day care centre, MCH- mother & child clinic,

a any illness,

b with respiratory tract infection,

c perinatal follow up HIV clinic used control group,

d routine check or immunisation,

e medical conditions as well as routine checks,

f minor illnesses no hospitalisations,

g some swabbed once others swabbed more than once,

h children and carers sick and well,

I adults also swabbed age not specified,

j hosp severe pneumonia,

k tuberculosis patients,

l year published,

m patients returning for review after minor illness.

The majority of the studies (87.7%) collected nasopharyngeal swabs, only 4(7.0%) collected oropharyngeal swabs, and 2(3.5%) studies collected both. In one study, the anatomical site of sampling was not reported. Calcium alginate was the most common type of swab 26 (45.6%). Other types used were cotton 7(12.3%), Dacron 3(5.3%), Rayon 4(7.0%), BBL 1(1.8%) and wire 3(5.3%). Thirteen studies (22.8%) did not report the type of swab that was used.

The majority of the studies (75.4%) were conducted in children, 11(19.3%) involved both children and adults and only 3(5.3%) studies exclusively recruited adults. Most studies (53.0%) were in healthy individuals, 14.0% had both healthy and sick patients, 24.5% were conducted in outpatients, 6.9% in HIV positive populations and in 1.7% the population was not stated. In 15(26.3%) studies, participants were swabbed more than once.

Pneumococcal carriage by age and geographic region

Carriage was highest for children less than 5 years and decreased with age (Table 2 and Figures S1, S2 & S3). High prevalence (>85%) in children were recorded in Ethiopia, Mozambique (only one study) and The Gambia. The Gambia also had the highest prevalence in adults (Table 2). The prevalence of carriage varied considerably between studies. The I2 index, which assesses heterogeneity between studies, was greater than 99% in all the age categories. In children less than 5 years the prevalence was higher in studies conducted in a rural, rather than urban setting. Carriage was not associated with season, population health, swab type or year (Table 3).

Table 2. Pneumococcal carriage prevalence in sub Saharan Africa by age.

A
First author, year Country Prevalence 95% CI % Wt
Hansman, 1977 Nigeria 44.4 34.6 54.2 2.50
Jacobs, 1977 South Africa 41.8 37.6 45.9 2.58
Klugman, 1977 South Africa 58.2 54.6 61.8 2.59
Ringertz, 1987 Ethiopia 89.8 88.0 91.6 2.60
Lloyd- Evans, 1989 Gambia 85.1 83.0 87.2 2.60
Rusen, 1990 Kenya 22.5 13.5 31.6 2.51
Woolfson, 1994 Zambia 71.9 66.4 77.4 2.57
Mthwalo, 1995 Lesotho 59.6 55.4 63.8 2.58
Yomo, 1995 Malawi 47.5 40.6 54.4 2.55
Rowe, 1995 CAR 71.2 66.8 75.6 2.58
Joloba, 1995 Uganda 61.8 54.9 68.7 2.55
Obaro, 1995 Gambia 93.8 90.1 97.5 2.59
Denno, 1996 Ghana 51.4 45.8 57.0 2.57
Kacou-Ndouba, 1997 Ivory Coast 63.3 56.9 69.7 2.56
Feikin, 1997 Malawi 87.0 84.8 89.2 2.59
Huebner, 1997 Botswana 69.1 63.6 74.5 2.57
Feikin, 1997 Malawi 84.0 81.6 86.4 2.59
Gordon, 1998 Malawi 42.0 35.4 48.1 2.56
Mbelle, 1999 South Africa 61.0 54.8 67.2 2.56
Huebner, 2000 South Africa 39.9 34.4 45.4 2.57
Obaro, 2000 Gambia 92.1 88.4 95.8 2.59
Bere, 2000 Burkina Faso 50.7 47.4 54.0 2.59
Adegbola, 2001 Gambia 87.0 80.5 93.5 2.55
McNally, 2001 South Africa 47.6 42.4 52.8 2.57
Darboe, 2001 Gambia 81.0 73.2 88.3 2.53
Cotton, 2002 South Africa 22.2 16.5 27.9 2.56
Hill, 2003 Gambia 93.4 88.7 98.1 2.58
Cheung, 2003 Gambia 86.1 84.0 88.2 2.60
Gill, 2003 Zambia 25.8 23.6 28.1 2.59
Nyandiko, 2003 Kenya 35.9 25.2 46.5 2.48
Valles, 2003 Mozambique 87.0 83.1 90.9 2.58
Haug, 2003 Ethiopia 93.3 88.8 97.8 2.58
Scott, 2004 Kenya 78.0 73.0 83.0 2.57
Abdullahi, 2004 Kenya 57.0 52.4 61.6 2.58
Abdullahi, 2006 Kenya 76.0 65.4 86.6 2.48
Hill, 2008 Gambia 86.0 81.6 90.4 2.58
Nwachukwu, 2008 Nigeria 69.0 58.2 79.8 2.47
Kacou-N'douba, 2010 Ivory Coast 27.5 24.7 30.3 2.59
Darboe, 2010 Gambia 21.0 15.3 26.7 2.56
Overall prevalence 63.2 55.6 70.8 100.00
I2(%), p-value 99.33, <0.001

(A) Children <5years, n = 15,879 (B) Children 5–15 years, n = 7,180 (C) Adults >15 years n = 5,350.

Table 3. Differences in the prevalence of pneumococcal carriage in sub Saharan Africa.

Prevalence (95%CI)
N+ Children <5 years pvalue N Children 5–15 years pvalue N Adults >15 years pvalue
Region
East 8 64.5(43.5–85.5) 0.73 4 42.5(−4.2–89.2) 0.72 2 12.2(−61.5–85.9) 0.06
Central 1 71.2 6 36.1(19.6–52.6) 0 -
Southern 15 56.4(44.8–67.9) 0 - 5 9.3(7.8–10.9)
West 15 68.8(55.3–82.) 3 54.9(−35.0–144.8) 6 49.3(19.2–79.3)
Settlement
Rural 16 80.2(70.5–89.9) <0.0001 5 55.7(16.1–95.3) 0.26 6 32.9(1.8–63.9) 0.44
Urban 15 53.4(45.2–61.7) 5 35.3(13.4–57.2) 4 19.5(−3.7–42.7)
Season
Dry 13 64.7(54.8–74.6) 0.54 5 31.4(11.4–51.3) na 3 9.6(6.6–12.6) na
Rainy 6 58.4(31.1–85.9) 0 - 0 -
Population a
Well 21 69.2(59.5–78.9) 0.11 8 44.3(19.1–69.5) 0.97 9 36.1(13.1–59.1) 0.33
Sickb 10 64.3(50.2–78.4) 3 35.5(−1.7–72.7) 0 -
HIV 1 22.2 1 55.0 2 13.3(−45.1–71.7)
Year c
Before 2000 19 63.7(54.4–72.9) 0.92 5 34.9(12.4–57.3) 0.39 4 10.8(7.7–13.8) 0.22
After 2000 20 62.8(50.4–75.3) 8 47.5(24.3–70.8) 9 34.8(11.2–58.3)
Swab route
NPS 37 64.6(57.1–72.2) na 11 48.1(32.8–63.3) 0.06 11 31.2(11.9–50.5) 0.67
OPS 0 - 2 13.3(−20.2–46.1) 1 18.0
Swab type
WHOd 21 60.9(50.5–71.3) 6 45.5(22.1–68.9) 6 22.3(−6.4–51.0)
Others 10 59.9(44.1–75.8) 0.91 5 36.9. (8.1–65.8) 0.55 6 26.3(3.84–48.9) 0.78

na- not applicable,

a excluded studies with both sick and well when prevalence was not available by category.

b all illnesses including pneumonia & upper respiratory tract infections.

c PCV first licensed 2000,

d WHO recommended calcium alginate & Dacro; p-values and prevalences based on meta-regression; N+ = no. of studies;

Data were used from N = 55 studies. Three studies contributed data to all three age groups, five studies contributed to <5 yrs and >15 yrs, 31 studies contributed to <5 yrs only, 10 studies contributed to 5–15 yrs only, and five studies contributed to >15 yrs only. Settlement, season, population, swab route and swab type were not recorded in all studies, and for these variables we have used studies where data were available.

Pneumococcal carriage and gender

Eleven studies reported the prevalence of carriage by gender. Three of these studies reported no association, one study reported a higher prevalence in males compared to females (p = 0.05), and one study reported a higher prevalence in females (OR = 0.61; 95% CI: 0.39–0.95; p = 0.02). From our analysis, there was no significant difference in the risk of carriage between males and females in any of the remaining six studies (Table 4).

Table 4. Prevalence of pneumococcal carriage in Africa by gender.

Country Ref Age grp Prevalence % (n/N) RD 95%CI Pvalue
Male Female
Uganda [51] Children 62.3 (66/106) 61.2(52/85) 0.01 −0.13,0.15 0.88
Uganda [55] Adults 25.9(28/108) 18.3(80/438) 0.08 −0.01,0.17 0.08
South Africaa [36] Children ns ns - 0.02
South Africab [45] Adults 8.8(75/854) 0.0(0/2) 0.09 na 1.00
Ghana [79] Infants 47.5 (75/158) 49.7(76/153) −0.02 −0.13, 0.09 0.73
Nigeria [37] Children (ns/55) (ns/45) - - 0.05
Zambia [64] Children 70.9 (93/131) 71.9(92/128) −0.01 −0.12,0.10 0.88
Kenyaa [6] All ages ns ns - - nd
Kenya [54] Children 32.3(11/34) 39.5(17/43) −0.07 −0.29,0.14 0.64
Gambia [83] All ages ns ns - nd
Malawi [66] Children 48.9(ns) 46.3(ns) 0.03 - nd

RD- Risk difference, ns- not stated, nd-no difference reported in paper, na – not applicable, Ref-reference,

a OR = 0.61 (95% CI: 0.39, 0.95),

b HIV infected mineworkers 99.8% male, p-value based on Fisher's exact test.

PCV and pneumococcal carriage

Seven studies from three countries (The Gambia, Kenya and South Africa) assessed the association between PCV and carriage. One study from the Gambia was a village cluster randomised trial with adults and older children in 10 villages receiving one dose of PCV 7, and adults and older children in 11 control villages receiving meningococcal serogroup C vaccine. In both arms of the trial, infants aged between 2 and 11 months received three doses of the vaccine given at monthly intervals, and children aged between 12 and 30 months received two doses at one month interval between doses. Infants born during the study received three doses of the vaccine given monthly at the ages 2, 3, and 4 months [24]. The other six studies compared carriage in vaccinated and unvaccinated children using data from individually randomised control trials (RCTs). Four of these studies collected carriage data on all children that participated in the trial [25][28] while two studies used data from a subsample of children enrolled in the original trial [29], [30] (Table 5).

Table 5. Studies of pneumococcal conjugate vaccination and carriage in Africa (n = 9,549).

Trial arm n/N (%)
1st Author Year Country Valency, Study design Age PCV administered (w/m/y) Age swabbed (w/m/y) Serotypes PCVb+c RD pvalue
SK Obaro 1995 Gambia PCV 5 2, 3,4 w PCV3+1 Control
PPV 18 m
RCTa 24 m Overall 22/26(84.6) 150/160(93.8) −0.09 0.112
VT 13/26(50.0) 144/160(90.0) −0.40 <0.001
NVT 20/26(76.9) 68/160(42.5) 0.34 0.001
N.Mbelle 1999 S. Africa PCV 9 6, 10,14 w PCV3 Control
RCT 6 w Overall 64/250(25.6) 74/250(29.6) −0.04 0.368
10 w Overall 110/249(44.2) 109/249(43.8) 0.004 1.000
14 w Overall 115/246(46.7) 127/247(51.4) −0.05 0.322
9 m Overall 130/242(53.7) 145/239(60.7) −0.07 0.140
VTd 43/242(17.8) 86/239(36.0) −0.18 <0.001
NVT 87/242(36.0) 59/239(24.7) 0.11 0.008
SK Obaro 2000 Gambia PCV 9 2, 3, 4 m PCV3 Control
RCT 5 m Overall 92/100(92.0) 94/102 (92.2) −0.002 1.000
VT 54/100(54.0) 64/102 (62.7) −0.09 0.253
NVT 45/100 (45.0) 33/102 (32.4) 0.13 0.083
9 m Overall 83/98 (84.7) 87/99(87.9) −0.03 0.541
VT 61/98(62.2) 74/99(74.7) −0.13 0.067
NVT 28/98(28.6) 16/99(16.2) 0.12 0.041
YB.Cheung 2003 Gambia PCV 9 2, 3, 4 m PCV3 Control
nested 9–15 m Overall 943/1078(87.5) 914/1061(86.1) 0.01 0.371
Cohort, VT 237/1051(22.5) 416/1041(40.0) −0.17 <0.001
RCT NVT 449/1051(42.7) 280/1041(26.9) 0.16 <0.001
21–27 m Overall 793/967(82.0) 813/961(84.6) −0.03 0.143
VT 230/922(24.9) 381/925(41.2) −0.16 <0.001
NVT 373/922(40.5) 242/925(26.2) 0.14 <0.001
J. A Scott* 2004/7 Kenya PCV 7 0 or 6 & 10, 14 w PCV3+1 e PCV3+1 f
PCV7/PPV 36 w 18 w Overallg 205/263(78.0) -
RCT VT ns(25.0) ns(31.0) −0.06 0.280
36 w Overallg 188/244(77.0) -
NVT ns(62.0) ns(51.0) 0.11 0.250
M.Ota* 2011 Gambia PCV 7 2, 3, 4 m PCV3+1 PCV1+1
PPV 10 m 5 m Overall 177/215(82.3) 178/217(82.0) 0.003 1.000
RCT VT 29/215(13.5) 43/217(19.8) −0.06 0.093
NVT 151/215(70.2) 138/217(63.6) 0.07 0.153
11 m Overall 143/200(71.5) 155/203(76.4) −0.05 0.307
VT 20/200(10.0) 41/203(20.2) −0.10 0.005
NVT 123/200(61.5) 117/203(57.6) 0.04 0.478
15 m Overall 159/194(82.0) 181/205(88.3) −0.06 0.090
VT 24/194(12.4) 38/205(18.5) −0.06 0.098
NVT 136/194(70.1) 149/205(72.7) −0.03 0.581
A.Roca* 2003/8 Gambia PCV 7 All ages PCV1 Control
clustered 2–5 yh Overall 79/90(87.8) 53/59(89.8) −0.02 0.796
RCT VT 18/90(20.0) 17/59(28.8) −0.09 0.239
NVT 61/90(67.6) 39/59(66.1) 0.02 0.860
2–5 yi Overall 23/30(76.7) 30/38(78.9) −0.02 1.000
VT 4/30(13.3) 9/38(23.7) −0.10 0.360
NVT 19/30(63. 6) 23/38(60.5) 0.03 1.000

w-weeks, m-months, y-years, RD- Risk difference- Risk in the PCV vaccinated group minus the risk in the control group calculated in Stata, PPV-Polyvalent polysaccharide vaccine, ns- not stated,

a children who received PCV 5 in an RCT and controls matched with age and place of residence who did not receive PCV, PCVb+c received b+c doses of PCV doses with

b for the primary series and

c for booster dose,

d includes vaccine associated serotypes.

e received PCV7 at 6, 10 and 14 weeks,

f received PCV7 at 6, 10 and 14 weeks or at 0, 10 and 14 weeks,

g Overall carriage for both groups,

h 4–6 months after vaccination,

i 22 months after vaccination;

these three studies were not included in the meta-analysis (in these 3 studies, both groups received PCV).P-value obtained using Fisher's exact test.

The participants in all the PCV studies were children from the general population presenting at infant welfare clinics for immunisation, except for the village cluster randomized trial which recruited children and adults in the community. Carriage of vaccine type (VT) serotypes was reduced by vaccination, while carriage of non-vaccine type serotypes was greater among vaccinated children (Figure 2 & Table 5). The prevalence of overall carriage was not affected by vaccination.

Figure 2. A comparison of pneumococcal carriage in vaccinated and unvaccinated children aged 9–24 months.

Figure 2

A positive risk difference indicates higher prevalence in the vaccinated arm.

Pneumococcal carriage serotypes in Africa

Twenty eight (49.1%) of the studies had collected data on serotypes and in total 6904 isolates were serotyped in these studies. The seven studies with PCV intervention were excluded from this analysis. There were 70 serotypes and serogroups. Serotype 19F was among the five most prevalent serotypes in 14/21 studies, serotype 6B in 13/21, serotype 14 in 13/21, serotype 6A in 11/21 and serotype 23F in 9/21 studies. Some studies only described serogroups, and in these studies serogroups 19 and 6 were the most common. In the PCV 9 vaccine trial in South Africa, serotypes 6B, 19F and 23F were the most common vaccine serotypes in both vaccinated (6B 3.3%, 19F 7.8%, 23F 2.9%) and control (6B 11.7%, 19F 13.4%, 23F 5.8%) groups, and serotype 6B and 19F were significantly less frequent in the PCV 9 vaccinated children. 15 (9.1%), 6A (5.8%) and 19A (2.9%) were the most common NVT serotypes/serogroup in the vaccinees, with serogroup 15 significantly increased in vaccinated compared to control children (9.1% versus 3.8%, p value 0.017) [28].

In The Gambia, the carriage study during the PCV 9 trial found that serotype 19F (11.5%) was again the most common VT serotype isolated and serogroup 15 was the most common NVT, and more prevalent in the PCV 9 vaccinated children (11.8% versus 8.5%, P<0.05). When the study children were swabbed a second time about 10 months later, NVT serotypes 10, 21 and 35B were isolated more frequently from PCV 9 vaccinated children than controls. There was no longer any difference between the groups for carriage of serotype 19F [29]. In the cluster randomised trial conducted in The Gambia, serotypes 23F, 6A, 6B, 3, 11 and 7C were the most common serotypes before vaccination and serotypes 3, 11, 19F and 6A were the most common serotypes after vaccination [24].

Discussion

This systematic review of pneumococcal carriage in sSA summarises the prevalence of carriage, distribution of serotypes and the effect of PCV on carriage. The majority of the studies were from Southern and West Africa, particularly South Africa and the Gambia. There were only two studies from Central Africa.

We found that the prevalence of pneumococcal carriage in sSA is generally high but there is much variation between countries, particularly among older age groups. Carriage was higher in children than adults as reported outside sSA [31], [32].

A small number of studies conducted outside sSA have reported a higher prevalence of carriage in males compared to females [33][35]. However, in this review gender was not associated with carriage in 9/11 studies, and in two studies carriage was more common among females [36], [37]. One of these studies was conducted in South Africa among children 1–59 months with severe pneumonia, 67.3% of whom were HIV positive and another was in Nigeria in children 1–4 years who presented for regular check-up or immunisation, some of whom had a cough and a cold.

The five serotypes that were most common in this review are among the seven that cause most global IPD in children; PCV 10 and PCV 13 will cover at least 70% of the cases of IPD caused by these serotypes [38], [39]. The other two serotypes, serotypes 1 and 5, are rarely isolated from carriage studies, although they are often associated with pneumococcal disease epidemics [40][42]. Serotypes also differ in their ability to cause invasive pneumococcal disease [43].

It has been suggested that the impact of PCV on disease can be determined by pneumococcal carriage studies because it is newly acquired serotypes that lead to disease [9]. In this review, studies that assessed the impact of PCV on carriage generally showed a decrease in carriage of VT and an increase in NVT serotypes, with no change in the overall prevalence of carriage. One study in this review, and one in native Indians have shown a gradual decrease in overall carriage following vaccination [24], [35]. Continuous surveillance of circulating serotypes will be important as countries introduce PCV.

Nasopharyngeal swabs are more sensitive for S.pneumoniae than the oral swabs [44], [45]. The prevalence of carriage is therefore likely to be underestimated in the four studies that used oral swabs. The different lab methods used might also have been responsible for some of the variability in the prevalence of carriage reported in this review. WHO recommends calcium alginate or Dacron polyester swabs since cotton swabs suppress the pneumococcus [23]. However, only half of the studies (50.9%) followed the WHO guidelines, and in 13 (22.4%) the type of swab was not stated.

Another source of variation between studies is the prevalence of antibiotic use, since antibiotics might reduce carriage [46]. Some studies excluded those individuals who had taken antibiotics from their analysis. However, even when these individuals were excluded, often different periods were used to define prior use.

We have combined results from all available published studies irrespective of the study population (unpublished studies were not included in this review). Study participants were recruited from the community, day care centres, schools and outpatient clinics and hospital wards. Hospital patients may have higher carriage than the rest of the population, particularly if they were admitted for pneumonia. Generally, we expect selection bias to be less in studies conducted in the community compared with studies that use outpatient clinics. In this review, 57.9% of the studies were conducted in hospital/clinic settings and 35.1% of the studies in the community.

We have summarised available data on pneumococcal carriage in sub Saharan Africa. There remain unexplained differences in carriage within the region, and multi centre studies may provide reasons for some of the differences seen. Pneumococcal carriage studies can show indirect effects of PCV by showing changes in unvaccinated age groups and can supplement disease surveillance studies as PCV is introduced in the region.

Supporting Information

Figure S1

Pneumococcal carriage in children <5 years. (Forest plot).

(TIF)

Figure S2

Pneumococcal carriage in children 5–15 years. (Forest plot).

(TIF)

Figure S3

Pneumococcal carriage in adults >15 years. (Forest plot).

(TIF)

Checklist S1

Prisma checklist.

(DOC)

Appendix S1

Search terms.

(DOCX)

Protocol S1

Study Protocol.

(DOCX)

Acknowledgments

Sincere thanks to Sara Thomas at the London School of Hygiene and Tropical Medicine for assistance with the development of the search strategy.

Funding Statement

This work was supported by a Medical Research Council PhD studentship awarded to EU. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1. Darboe MK, Fulford AJ, Secka O, Prentice AM (2010) The dynamics of nasopharyngeal streptococcus pneumoniae carriage among rural Gambian mother-infant pairs. BMC Infect Dis 10: 195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Hill PC, Yin BC, Akisanya A, Sankareh K, Lahai G, et al. (2008) Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: A longitudinal study. Clinical Infectious Diseases 46: 807–14. [DOI] [PubMed] [Google Scholar]
  • 3. Gray BM, Turner ME, Dillon HC Jr (1982) Epidemiologic studies of Streptococcus pneumoniae in infants. The effects of season and age on pneumococcal acquisition and carriage in the first 24 months of life. Am J Epidemiol 116: 692–703. [DOI] [PubMed] [Google Scholar]
  • 4. Huang SS, Finkelstein JA, Rifas-Shiman SL, Kleinman K, Platt R (2004) Community-level predictors of pneumococcal carriage and resistance in young children. Am J Epidemiol 159: 645–54. [DOI] [PubMed] [Google Scholar]
  • 5. Regev-Yochay G, Raz M, Dagan R, Porat N, Shainberg B, et al. (2004) Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 38: 632–9. [DOI] [PubMed] [Google Scholar]
  • 6. Abdullahi O, Nyiro J, Lewa P, Slack M, Scott JAG (2008) The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi District, Kenya. Pediatric Infectious Disease Journal 27: 59–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Bogaert D, De Groot R, Hermans PW (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4: 144–54. [DOI] [PubMed] [Google Scholar]
  • 8. Rinta-Kokko H, Dagan R, Givon-Lavi N, Auranen K (2009) Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine 27: 3831–7. [DOI] [PubMed] [Google Scholar]
  • 9. Gray BM, Converse GM 3rd, Dillon HC Jr (1980) Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 142: 923–33. [DOI] [PubMed] [Google Scholar]
  • 10. Faden H, Duffy L, Wasielewski R, Wolf J, Krystofik D, et al. (1997) Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis 175: 1440–5. [DOI] [PubMed] [Google Scholar]
  • 11. Syrjanen RK, Kilpi TM, Kaijalainen TH, Herva EE, Takala AK (2001) Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. J Infect Dis 184: 451–9. [DOI] [PubMed] [Google Scholar]
  • 12. Vu HT, Yoshida LM, Suzuki M, Nguyen HA, Nguyen CD, et al. (2011) Association between nasopharyngeal load of Streptococcus pneumoniae, viral coinfection, and radiologically confirmed pneumonia in Vietnamese children. Pediatr Infect Dis J 30: 11–8. [DOI] [PubMed] [Google Scholar]
  • 13. Yang S, Lin S, Khalil A, Gaydos C, Nuemberger E, et al. (2005) Quantitative PCR assay using sputum samples for rapid diagnosis of pneumococcal pneumonia in adult emergency department patients. J Clin Microbiol 43: 3221–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. O'Brien KL, Millar EV, Zell ER, Bronsdon M, Weatherholtz R, et al. (2007) Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 196: 1211–20. [DOI] [PubMed] [Google Scholar]
  • 15. Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, et al. (2004) Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113: 443–9. [DOI] [PubMed] [Google Scholar]
  • 16. Guevara M, Barricarte A, Gil-Setas A, Garcia-Irure JJ, Beristain X, et al. (2009) Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 15: 1013–9. [DOI] [PubMed] [Google Scholar]
  • 17. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, et al. (2009) Changing epidemiology of invasive pneumococcal disease in Canada, 1998–2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 49: 205–12. [DOI] [PubMed] [Google Scholar]
  • 18. Roche PW, Krause V, Cook H, Barralet J, Coleman D, et al. (2008) Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell 32: 18–30. [PubMed] [Google Scholar]
  • 19. Williams SR, Mernagh PJ, Lee MH, Tan JT (2011) Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine. Med J Aust 194: 116–20. [DOI] [PubMed] [Google Scholar]
  • 20. Levy C, Varon E, Bingen E, Lecuyer A, Boucherat M, et al. (2011) PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 30: 168–70. [DOI] [PubMed] [Google Scholar]
  • 21. Ho PL, Chiu SS, Ang I, Lau YL (2011) Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae before and after introduction of 7-valent pneumococcal conjugate vaccine, Hong Kong, 1995–2009. Vaccine 29: 3270–5. [DOI] [PubMed] [Google Scholar]
  • 22. Fenoll A, Aguilar L, Vicioso MD, Gimenez MJ, Robledo O, et al. (2011) Increase in serotype 19A prevalence and amoxicillin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997–2009. BMC Infect Dis 11: 239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. O'Brien KL, Nohynek H (2003) Report from a WHO Working Group: standard method for detecting upper respiratory carriage of Streptococcus pneumoniae. Pediatr Infect Dis J 22: e1–11. [DOI] [PubMed] [Google Scholar]
  • 24. Roca A, Hill PC, Townend J, Egere U, Antonio M, et al. (2011) Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med 8: e1001107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Obaro SK, Adegbola RA, Chang I, Banya WAS, Jaffar S, et al. (2000) Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants. Pediatric Infectious Disease Journal 19: 463–9. [DOI] [PubMed] [Google Scholar]
  • 26. Ota MO, Akinsola A, Townend J, Antonio M, Enwere G, et al. (2011) The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule. Vaccine 29: 2999–3007. [DOI] [PubMed] [Google Scholar]
  • 27. Scott JA, Ojal J, Ashton L, Muhoro A, Burbidge P, et al. (2011) Pneumococcal conjugate vaccine given shortly after birth stimulates effective antibody concentrations and primes immunological memory for sustained infant protection. Clin Infect Dis 53: 663–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Mbelle N, Huebner RE, Wasas AD, Kimura A, Chang I, et al. (1999) Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 180: 1171–6. [DOI] [PubMed] [Google Scholar]
  • 29. Cheung YB, Zaman SM, Nsekpong ED, Van Beneden CA, Adegbola RA, et al. (2009) Nasopharyngeal Carriage of Streptococcus pneumoniae in Gambian Children who Participated in a 9-valent Pneumococcal Conjugate Vaccine Trial and in Their Younger Siblings. Pediatr Infect Dis J [DOI] [PubMed] [Google Scholar]
  • 30. Obaro SK, Adegbola RA, Banya WA, Greenwood BM (1996) Carriage of pneumococci after pneumococcal vaccination. Lancet 348: 271–2. [DOI] [PubMed] [Google Scholar]
  • 31. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995–1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729–35. [DOI] [PubMed] [Google Scholar]
  • 32. Trotter CL, Waight P, Andrews NJ, Slack M, Efstratiou A, et al. (2010) Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: England and Wales, 1996–2006. J Infect 60: 200–8. [DOI] [PubMed] [Google Scholar]
  • 33. Millar EV, O'Brien KL, Zell ER, Bronsdon MA, Reid R, et al. (2009) Nasopharyngeal carriage of Streptococcus pneumoniae in Navajo and White Mountain Apache children before the introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J 28: 711–6. [DOI] [PubMed] [Google Scholar]
  • 34. Mackenzie GA, Leach AJ, Carapetis JR, Fisher J, Morris PS (2010) Epidemiology of nasopharyngeal carriage of respiratory bacterial pathogens in children and adults: cross-sectional surveys in a population with high rates of pneumococcal disease. BMC Infect Dis 10: 304. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Scott JR, Millar EV, Lipsitch M, Moulton LH, Weatherholtz R, et al. (2012) Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis 205: 280–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. McNally LM, Jeena PM, Gajee K, Sturm AW, Tomkins AM, et al. (2006) Lack of association between the nasopharyngeal carriage of Streptococcus pneumoniae and Staphylococcus aureus in HIV-1-infected South African children. Journal of Infectious Diseases 194: 385–90. [DOI] [PubMed] [Google Scholar]
  • 37. Nwachukwu NOA (2008) Streptococcus Pneumoniae carriage rates among infants in Owerri Nigeria. MERA: African Journal of Respiratory Medicine 16. [Google Scholar]
  • 38. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, et al. (2010) Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med 7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Publication WHO (2012) Pneumococcal vaccines WHO position paper - 2012 - recommendations. Vaccine 2012 30: 4717–8. [DOI] [PubMed] [Google Scholar]
  • 40. Dagan R, Gradstein S, Belmaker I, Porat N, Siton Y, et al. (2000) An outbreak of Streptococcus pneumoniae serotype 1 in a closed community in southern Israel. Clin Infect Dis 30: 319–21. [DOI] [PubMed] [Google Scholar]
  • 41. Antonio M, Hakeem I, Awine T, Secka O, Sankareh K, et al. (2008) Seasonality and outbreak of a predominant Streptococcus pneumoniae serotype 1 clone from The Gambia: Expansion of ST217 hypervirulent clonal complex in West Africa. BMC Microbiology 8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Smith-Vaughan H, Marsh R, Mackenzie G, Fisher J, Morris PS, et al. (2009) Age-specific cluster of cases of serotype 1 Streptococcus pneumoniae carriage in remote indigenous communities in Australia. Clin Vaccine Immunol 16: 218–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Brueggemann AB, Griffiths DT, Meats E, Peto T, Crook DW, et al. (2003) Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype- and clone-specific differences in invasive disease potential. J Infect Dis 187: 1424–32. [DOI] [PubMed] [Google Scholar]
  • 44. Capeding MR, Nohynek H, Sombrero LT, Pascual LG, Sunico ES, et al. (1995) Evaluation of sampling sites for detection of upper respiratory tract carriage of Streptococcus pneumoniae and Haemophilus influenzae among healthy Filipino infants. J Clin Microbiol 33: 3077–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Pemba L, Charalambous S, von Gottberg A, Magadla B, Moloi V, et al. (2008) Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. [DOI] [PubMed] [Google Scholar]
  • 46. Varon E, Levy C, De La Rocque F, Boucherat M, Deforche D, et al. (2000) Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Clin Infect Dis 31: 477–81. [DOI] [PubMed] [Google Scholar]
  • 47. Rowe AK, Deming MS, Schwartz B, Wasas A, Rolka D, et al. (2000) Antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae and Haemophilus influenzae from children in the Central African Republic. [DOI] [PubMed] [Google Scholar]
  • 48. Ndip RN, Ntiege EA, Ndip LM, Nkwelang G, Akoachere JF, et al. (2008) Antimicrobial resistance of bacterial agents of the upper respiratory tract of school children in Buea, Cameroon. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ringertz S, Muhe L, Krantz I, Hathaway A, Shamebo D, et al.. (1993) Prevalence of potential respiratory disease bacteria in children in Ethiopia. Antimicrobial susceptibility of the pathogens and use of antibiotics among the children. [DOI] [PubMed]
  • 50. Rusen ID, Fraser-Roberts L, Slaney L, Ombette J, Lovgren M, et al. (1997) Nasopharyngeal pneumococcal colonization among Kenyan children: antibiotic resistance, strain types and associations with human immunodeficiency virus type 1 infection. [DOI] [PubMed] [Google Scholar]
  • 51. Joloba ML, Bajaksouzian S, Palavecino E, Whalen C, Jacobs MR (2001) High prevalence of carriage of antibiotic-resistant Streptococcus pneumoniae in children in Kampala Uganda. [DOI] [PubMed] [Google Scholar]
  • 52. Batt SL, Charalambous BM, Solomon AW, Knirsch C, Massae PA, et al. (2003) Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Scott JAG, Hall AJ, Hannington A, Edwards R, Mwarumba S, et al. (1998) Serotype distribution and prevalence of resistance to benzylpenicillin in three representative populations of Streptococcus pneumoniae isolates from the coast of Kenya. Clinical Infectious Diseases 27: 1442–50. [DOI] [PubMed] [Google Scholar]
  • 54. Nyandiko WM, Greenberg D, Shany E, Yiannoutsos CT, Musick B, et al. (2007) Nasopharyngeal Streptococcus pneumoniae among under-five year old children at the Moi Teaching and Referral Hospital, Eldoret, Kenya. [PubMed] [Google Scholar]
  • 55. Blossom DB, Namayanja-Kaye G, Nankya-Mutyoba J, Mukasa JB, Bakka H, et al. (2006) Oropharyngeal colonization by Streptococcus pneumoniae among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Abdullahi O, Wanjiru E, Musyimi R, Glass N, Scott JA (2007) Validation of nasopharyngeal sampling and culture techniques for detection of Streptococcus pneumoniae in children in Kenya. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, et al. (2010) The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis 51: 571–4. [DOI] [PubMed] [Google Scholar]
  • 58. Skalet AH, Cevallos V, Ayele B, Gebre T, Zhou Z, et al. (2010) Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med 7: e1000377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Jacobs MR, Koornhof HJ, Robins-Browne RM, Stevenson CM, Vermaak ZA, et al. (1978) Emergence of multiply resistant pneumococci. [DOI] [PubMed] [Google Scholar]
  • 60. Klugman KP, Koornhof HJ, Kuhnle V (1998) Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci. American Journal of Diseases of Children 140: 1186–90. [DOI] [PubMed] [Google Scholar]
  • 61. Robins-Browne RM, Kharsany AB, Koornhof HJ (1984) Antibiotic-resistant pneumococci in hospitalized children. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Oppenheim B, Koornhof HJ, Austrian R (1986) Antibiotic-resistant pneumococcal disease in children at Baragwanath Hospital, Johannesburg. [DOI] [PubMed] [Google Scholar]
  • 63. Frederiksen B, Henrichsen J (1988) Throat carriage of Streptococcus pneumoniae and Streptococcus pyogenes among infants and children in Zambia. [DOI] [PubMed] [Google Scholar]
  • 64. Woolfson A, Huebner R, Wasas A, Chola S, Godfrey-Faussett P, et al. (1997) Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. [PMC free article] [PubMed] [Google Scholar]
  • 65. Mthwalo M, Wasas A, Huebner R, Koornhof HJ, Klugman KP (1998) Antibiotic resistance of nasopharyngeal isolates of Streptococcus pneumoniae from children in Lesotho. [PMC free article] [PubMed] [Google Scholar]
  • 66. Yomo A, Subramanyam VR, Fudzulani R, Kamanga H, Graham SM, et al. (1997) Carriage of penicillin-resistant pneumococci in Malawian children. [DOI] [PubMed] [Google Scholar]
  • 67. Feikin DR, Dowell SF, Nwanyanwu OC, Klugman KP, Kazembe PN, et al. (2000) Increased carriage of trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae in Malawian children after treatment for malaria with sulfadoxine/pyrimethamine. [DOI] [PubMed] [Google Scholar]
  • 68. Feikin DR, Davis M, Nwanyanwu OC, Kazembe PN, Barat LM, et al. (2003) Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. [PubMed] [Google Scholar]
  • 69. Huebner RE, Wasas A, Mushi A, Mazhani L, Klugman K (1998) Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. [DOI] [PubMed] [Google Scholar]
  • 70. Gordon SB, Kanyanda S, Walsh AL, Goddard K, Chaponda M, et al. (2003) Poor potential coverage for 7-valent pneumococcal conjugate vaccine, Malawi. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ (2008) High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Valles X, Flannery B, Roca A, Mandomando I, Sigauque B, et al. (2006) Serotype distribution and antibiotic susceptibility of invasive and nasopharyngeal isolates of Streptococcus pneumoniae among children in rural Mozambique. Trop Med Int Health 11: 358–66. [DOI] [PubMed] [Google Scholar]
  • 73. von Gottberg A, Klugman KP, Cohen C, Wolter N, de Gouveia L, et al. (2008) Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.[see comment]. [DOI] [PubMed] [Google Scholar]
  • 74. Huebner RE, Wasas AD, Klugman KP (2000) Prevalence of nasopharyngeal antibiotic-resistant pneumococcal carriage in children attending private paediatric practices in Johannesburg. S Afr Med J 90: 1116–21. [PubMed] [Google Scholar]
  • 75. Mwenya DM, Charalambous BM, Phillips PP, Mwansa JC, Batt SL, et al. (2010) Impact of cotrimoxazole on carriage and antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae in HIV-infected children in Zambia. Antimicrob Agents Chemother 2010;54: 3756–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Marcus L, van Dyk JC (1996) Incidence of asymptomatic carriage of potentially pathogenic respiratory organisms among preschool Pretoria children. S Afr Med J 86: 1132, 4. [PubMed] [Google Scholar]
  • 77. Hansman D (1978) Cloramphenicol-resistant pneumococci in West Africa. Lancet 1102. [DOI] [PubMed] [Google Scholar]
  • 78. Lloyd-Evans N, O'Dempsey TJD, Baldeh I, Secka O, Demba E, et al. (1996) Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatric Infectious Disease Journal 15: 866–71. [DOI] [PubMed] [Google Scholar]
  • 79. Denno DM, Frimpong E, Gregory M, Steele RW (2002) Nasopharyngeal carriage and susceptibility patterns of Streptococcus pneumoniae in Kumasi, Ghana. [PubMed] [Google Scholar]
  • 80. Kacou-N'Douba A, Bouzid SA, Guessennd KN, Kouassi-M'Bengue AA, Faye-Kette AY, et al. (2001) Antimicrobial resistance of nasopharyngeal isolates of Streptococcus pneumoniae in healthy carriers: report of a study in 5-year-olds in Marcory, Abidjan, Cote d'Ivoire. [DOI] [PubMed] [Google Scholar]
  • 81. Darboe MK, Thurnham DI, Morgan G, Adegbola RA, Secka O, et al. (2007) Effectiveness of an early supplementation scheme of high-dose vitamin A versus standard WHO protocol in Gambian mothers and infants: a randomised controlled trial.[see comment]. [DOI] [PubMed] [Google Scholar]
  • 82. Adegbola RA, Obaro SK, Biney E, Greenwood BM (2001) Evaluation of Binax now Streptococcus pneumoniae urinary antigen test in children in a community with a high carriage rate of pneumococcus. [DOI] [PubMed] [Google Scholar]
  • 83. Hill PC, Akisanya A, Sankareh K, Cheung YB, Saaka M, et al. (2006) Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian villagers. Clinical Infectious Diseases 43: 673–9. [DOI] [PubMed] [Google Scholar]
  • 84. Bere LC, Simpore J, Karou SD, Zeba B, Bere AP, et al. (2009) Antimicrobial resistance and serotype distribution of Streptococcus pneumoniae strains causing childhood infection in Burkina Faso. Pak J Biol Sci 12: 1282–6. [DOI] [PubMed] [Google Scholar]
  • 85. Kandakai-Olukemi YT, Dido MS (2009) Antimicrobial resistant profile of Streptococcus pneumoniae isolated from the nasopharynx of secondary school students in Jos, Nigeria. Ann Afr Med 8: 10–3. [DOI] [PubMed] [Google Scholar]
  • 86. Mureithi MW, Finn A, Ota MO, Zhang Q, Davenport V, et al. (2009) T cell memory response to pneumococcal protein antigens in an area of high pneumococcal carriage and disease. J Infect Dis 200: 783–93. [DOI] [PubMed] [Google Scholar]
  • 87. Donkor ES, Newman MJ, Oliver-Commey J, Bannerman E, Dayie NT, et al. (2010) Invasive disease and paediatric carriage of Streptococcus pneumoniae in Ghana. Scand J Infect Dis 42: 254–9. [DOI] [PubMed] [Google Scholar]
  • 88. Hill PC, Townend J, Antonio M, Akisanya B, Ebruke C, et al. (2010) Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 50: 1468–76. [DOI] [PubMed] [Google Scholar]
  • 89. Kacou-N'douba A, Okpo SC, Ekaza E, Pakora A, Koffi S, et al. (2010) Emergence of optochin resistance among S. pneumoniae strains colonizing healthy children in Abidjan. Indian J Med Microbiol 28: 80–1. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Figure S1

Pneumococcal carriage in children <5 years. (Forest plot).

(TIF)

Figure S2

Pneumococcal carriage in children 5–15 years. (Forest plot).

(TIF)

Figure S3

Pneumococcal carriage in adults >15 years. (Forest plot).

(TIF)

Checklist S1

Prisma checklist.

(DOC)

Appendix S1

Search terms.

(DOCX)

Protocol S1

Study Protocol.

(DOCX)


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES